The National Health Surveillance Agency (Anvisa) approved the registration of the first vaccine to prevent bronchiolitis in babies, in publication in the Official Gazette of the Union (DOU) on Monday (01).
The vaccine is intended to combat respiratory syncytial virus (RSV), which causes respiratory tract infections, especially bronchiolitis. The disease is an inflammation of the bronchi — organs that ensure that air is taken to the lungs — and has a higher incidence in babies.
The Abrysvo vaccine, from the company Pfizer, will not be administered to children, but to mothers during pregnancy. The vaccine is indicated for the prevention of lower respiratory tract disease and severe lower respiratory tract disease from birth to 6 months of age.
The registry was also approved for the application of lower respiratory tract disease caused by RSV in people aged 60 or over, considered to be at risk for the disease.
According to Anvisa's analysis, the main side effects were pain at the application site, which is intramuscular, headache and muscle pain. The vaccine is considered bivalent, as it has two antigens from the RSV F surface protein. The application will be in a single dose, being administered between the second or third trimester of pregnancy.
In December 2023, Anvisa had already authorized the registration of the Arexvy vaccine, from manufacturer GlaxoSmith Kline, also to prevent diseases caused by RSV, but use was restricted to people over 60 years of age.
Source: CNN Brasil
I’m James Harper, a highly experienced and accomplished news writer for World Stock Market. I have been writing in the Politics section of the website for over five years, providing readers with up-to-date and insightful information about current events in politics. My work is widely read and respected by many industry professionals as well as laymen.
